title: FDA notifications.  Genentech issues letter about Fuzeon® co-product.
mesh_terms: D017277:Drug Approval / Q000331:legislation & jurisprudence*; D056736:Drug Recalls; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D010446:Peptide Fragments / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D015700:HIV Envelope Protein gp41; D010446:Peptide Fragments; D000077560:Enfuvirtide